Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
6 Months : From Oct 2019 to Apr 2020
By Patrick Thomas
Johnson & Johnson (JNJ) shares rose 2.2% Wednesday following better-than-expected quarterly earnings earlier this week and after The Wall Street Journal reported it was involved in discussions to contribute additional money to a sweeping opioid crisis settlement.
Three major drug distributors are in talks to pay $18 billion over 18 years to settle litigation brought by state and local governments blaming them for fueling the opioid crisis, the Journal reported.
Shares of McKesson Corp. (MCK) rose 7.3%, AmerisourceBergen (ABC) shares rose 6.3% and Cardinal Health Inc. (CAH) shares rose about 5.5% Wednesday.
On Tuesday, J&J raised its financial forecast for the rest of 2019, despite grappling with a heavy case load of litigation, as it reported quarterly results that were above Wall Street estimates, boosted by gains in its consumer and pharmaceuticals divisions.
"JNJ will remain a relative safe haven in a volatile market as investors and companies digest the potential impact from political uncertainty both in the U.S. and abroad," analysts at SVB Leerink said in a research note. "JNJ delivered a strong quarter with continued growth momentum across all segments, and more importantly, this momentum seems to be sustainable into 4Q19 and 2020."
Also on Tuesday, a Missouri state appeals court reversed a $110 million jury award in 2017 to a Virginia woman who claimed her use of J&J's talcum powder caused ovarian cancer. The appeals court cited lack of jurisdiction. Attorneys for the woman plan to appeal the ruling.
Write to Patrick Thomas at email@example.com
(END) Dow Jones Newswires
October 16, 2019 10:56 ET (14:56 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.